These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 17717969)

  • 1. Glatiramer in the treatment of multiple sclerosis.
    Rizvi SA; Kim E; Moodie J
    Int J Nanomedicine; 2006; 1(3):283-9. PubMed ID: 17717969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate in multiple sclerosis.
    Mezzapesa DM; Rovaris M; Filippi M
    Expert Rev Neurother; 2005 Jul; 5(4):451-8. PubMed ID: 16026228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J
    Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.
    Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M;
    Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M; Miravalle A; Vollmer T
    J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA; Rovaris M; Goodman AD; Ladkani D; Wynn D; Filippi M;
    Neurology; 2007 Mar; 68(12):939-44. PubMed ID: 17372130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow up of glatiramer acetate compassionate use in Belgium.
    Sindic CJ; Seeldrayers P; Vande Gaer L; De Smet E; Nagels G; De Deyn PP; Medaer R; Guillaume D; D'Hooghe MB; Deville MC; Decoo D; Sadzot B; Van Landegem W; Strauven T; Pepin J; Merckx H; Caekebeke J; van der Tool MA
    Acta Neurol Belg; 2005 Jun; 105(2):81-5. PubMed ID: 16076061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New options for early treatment of multiple sclerosis.
    Tintoré M
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying drugs for multiple sclerosis: current and future aspects.
    Freedman MS
    Expert Opin Pharmacother; 2006 Oct; 7 Suppl 1():S1-9. PubMed ID: 17020427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Newer disease--modifying drugs: glatiramer acetate and mitoxantrone].
    Kohriyama T; Higaki M; Matsumoto M
    Nihon Rinsho; 2003 Aug; 61(8):1381-7. PubMed ID: 12962027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.
    Ytterberg C; Johansson S; Andersson M; Olsson D; Link H; Holmqvist LW; von Koch L
    Acta Neurol Scand; 2007 Aug; 116(2):96-9. PubMed ID: 17661794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate (Copaxone).
    Francis DA
    Int J Clin Pract; 2001; 55(6):394-8. PubMed ID: 11501229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
    Moreau T
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
    Racke MK; Lovett-Racke AE; Karandikar NJ
    Neurology; 2010 Jan; 74 Suppl 1():S25-30. PubMed ID: 20038760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.
    Lopez-Diego RS; Weiner HL
    Nat Rev Drug Discov; 2008 Nov; 7(11):909-25. PubMed ID: 18974749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone.
    Charach G; Grosskopf I; Weintraub M
    Digestion; 2008; 77(3-4):198-200. PubMed ID: 18607107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.